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From April 2009 through March 2010, during the 
pandemic (H1N1) 2009 outbreak, ≈8.2 million prescriptions 
for inﬂ  uenza neuraminidase-inhibiting antiviral drugs were 
ﬁ   lled in the United States. We estimated the number of 
hospitalizations likely averted due to use of these antiviral 
medications. After adjusting for prescriptions that were 
used for prophylaxis and personal stockpiles, as well 
as for patients who did not complete their drug regimen, 
we estimated the ﬁ   lled prescriptions prevented ≈8,400–
12,600 hospitalizations (on the basis of median values). 
Approximately 60% of these prevented hospitalizations 
were among adults 18–64 years of age, with the remainder 
almost equally divided between children 0–17 years of age 
and adults >65 years of age. Public health ofﬁ  cials should 
consider these estimates an indication of success of treating 
patients during the 2009 pandemic and a warning of the 
need for renewed planning to cope with the next pandemic.
F
rom April 23, 2009, through April 10, 2010, it is 
estimated that pandemic (H1N1) 2009 virus caused 
≈61 million cases of inﬂ  uenza (range 43–89 million cases), 
≈270,000 related hospitalizations (range 195,000–403,000 
hospitalizations), and ≈12,500 deaths (range 8,900–
18,300 deaths) in the United States (1). Even before the 
impact was fully known, the Centers for Disease Control 
and Prevention (CDC) recommended prompt empiric 
treatment with inﬂ   uenza antiviral drugs, principally 
the neuraminidase-inhibiting inﬂ   uenza antiviral drugs 
oseltamivir and zanamivir, of persons with suspected or 
conﬁ  rmed inﬂ  uenza and who also met >1 of the following 
conditions: 1) illness that required hospitalization; 2) 
progressive, severe, or complicated illness, regardless of 
previous health status; and 3) risk for severe disease (e.g., 
patients with asthma, neurologic and neurodevelopmental 
conditions; chronic lung or heart disease; blood, endocrine, 
kidney, liver, and metabolic disorders; pregnancy; and 
those who were old or young) (2). The primary goal of these 
recommendations was to reduce the number and severity of 
pandemic (H1N1) 2009 cases, especially hospitalizations.
We present estimates of the number of pandemic 
(H1N1) 2009–related hospitalizations, by age group, 
averted because of use of antiviral drugs given to treat 
clinical cases of inﬂ  uenza. These results can be used by 
public health policy makers to plan and prepare for the next 
pandemic. For example, these estimates can be used to help 
evaluate the policy option of replenishing state and federal 
inﬂ  uenza antiviral drug stockpiles
Methods
We developed a spreadsheet-based model to 
calculate the number of pandemic (H1N1) 2009–related 
hospitalizations averted because of treatment with the 
neuraminidase-inhibiting inﬂ   uenza antiviral drugs 
oseltamivir and zanamivir (online Technical Appendix, 
www.cdc.gov/EID/content/17/9/110295-Techapp.htm). 
The risk for hospitalization (and thus potential beneﬁ  t from 
antiviral drugs) differed by age groups (1). Therefore, we 
estimated the reduced number of hospitalizations separately 
for 3 groups: persons 0–17 years of age, 18–64 years of age, 
and >65 years of age. We calculated the hospitalizations 
averted by using the following general equation: no. 
hospitalizations averted (by age group) = [no. prescriptions 
written – estimated no. written for prophylaxis, stockpiling, 
or incomplete adherence to drug regimen] × age group–
speciﬁ   c risk for hospitalizations caused by pandemic 
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(H1N1) 2009 × age group–speciﬁ  c effectiveness of drugs 
in preventing hospitalizations.
Prescriptions Filled
We used the number of prescriptions ﬁ  lled for these 
drugs for weeks ending April 24, 2009, through March 
26, 2010 (Table 1), collected from the IMS Health (IMS) 
Xponent proprietary prescription database (IMS Health, 
Norwalk, CT, USA) (3). This database contains all retail 
prescriptions ﬁ  lled from a representative sample of 35,000 
(73%) of ≈50,000 US-based retail pharmacies, including 
independent pharmacies, chain pharmacies, pharmacies 
in discount outlets, pharmacies in food stores, mail order 
pharmacies, and pharmacy beneﬁ  t management companies. 
IMS then proportionately extrapolates their data on the 
basis of populations served by the included pharmacies to 
provide weekly estimates of all prescriptions ﬁ  lled in the 
United States for these drugs. The Xponent database does 
not track prescriptions ﬁ   lled by in-hospital pharmacies. 
Therefore, in-hospital prescriptions are not part of our 
calculations.
The IMS Xponent database captures all ﬁ  lled 
prescriptions related to inﬂ  uenza antiviral drugs within 
its sample pharmacies. However, it does not identify 
the source of the drugs. During 2009, there were 2 
main potential supplies for the antiviral drugs—the 
regular commercial supply system and state and federal 
government-maintained drug stockpiles. The IMS 
database does not track medications dispensed from 
public domains, such as public health departments. 
Furthermore, the federal and state stockpiles of antiviral 
drugs were meant to supplement the commercial supply 
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Table 1. Number of pandemic (H1N1) 2009 cases versus number of influenza antiviral prescriptions filled during pandemic (H1N1) 
2009 outbreak, United States, April 24, 2009–March 26, 2010*
Week† Mid-level estimate of cases‡ 
Filled influenza antiviral prescriptions 
Oseltamivir Zanamivir Total
2009 Apr–Jul  3,052,768  1,243,827  69,513  1,313,340 
2009 Aug  1,605,760  342,386  11,645  354,031 
35 626,256 146,282  5,097  151,379 
36 1,675,630 234,211  7,171  241,382 
37 1,302,846 265,626  7,892  273,518 
38 1,508,514 331,060  8,735  339,795 
39 2,319,691 383,759  9,981  393,740 
40 4,461,542 435,546  11,625  447,171 
41 6,549,205 471,323  11,226  482,549 
42 7,120,298 527,362  11,218  538,580 
43 6,297,210 671,741  12,046  683,787 
44 5,899,647 640,887  9,306  650,193 
45 5,013,181 537,781  6,338  544,119 
46 3,350,286 386,569  4,863  391,432 
47 1,767,166 273,092  3,039  276,131 
48 1,020,606 152,482  1,857  154,339 
49 804,901 133,998  1,782  135,780 
50 646,358 99,565  1,348  100,913 
51 612,204 88,718  1,338  90,056 
52 619,080 64,807  1,010  65,817 
1 418,803 56,569  1,009  57,578 
2 520,390 50,642  981 51,651 
3 516,958 50,326  1,057  51,307 
4 356,400 44,770  1,048  45,827 
5 493,448 43,757  1,211  44,805 
6 322,623 42,474  1,251  43,685 
7 312,327 43,809  1,228  45,060 
8 281,986 47,146  1,487  48,374 
9 245,707 48,671  1,494  50,158 
10 288,215 47,261  1,587  48,755 
11 225,448 33,867  1,043  34,910 
12 312,575 26,072  730 26,802 
Total 60,548,030 7,966,386 211,156 8,177,542
*IMS Health Xponent database (3) includes 57,544 oseltamivir prescriptions and 877 zanamivir prescriptions for week 53. Because the Centers for 
Disease Control and Prevention only reports 52 weeks for 2009, we removed week 53 from the IMS data set (IMS Health, Norwalk, CT, USA).  
†Estimates of cases for April–August 2009 are not available on a weekly basis. 
‡Mid-level weekly cases estimated from (1) and www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.  Effect of Antiviral Drug Use during Pandemic
chain in times of drug shortages anticipated to occur 
during a pandemic emergency.
As of August 2010, the estimated total amount of 
antiviral drugs managed by states throughout the pandemic 
was 38 million treatment regimens. This estimate includes 
antiviral drugs purchased by states (26 million treatment 
regimens) plus ≈12 million treatment regimens distributed 
early in the pandemic to states from the CDC Strategic 
National Stockpile (SNS). Preliminary reports from state 
public health departments to the CDC show that most SNS 
product was either retained by the health departments or 
deployed at the local level (to dispensing sites such as drug 
stores and health departments). Sites received directions 
that the SNS-provided supplies were to be dispensed if 
commercial supplies could not keep up with demand or 
used to treat uninsured or underinsured persons who could 
otherwise not afford treatment. Preliminary data reported 
to CDC through SNS show that minimum quantities 
of stockpiled antiviral drugs were actually dispensed 
to patients. Because the commercial supply chain for 
antiviral drugs remained relatively robust, most states did 
not need to use stockpiled antiviral drugs. Therefore, we 
did not include any estimates of impact on antiviral drugs 
dispensed from these government stockpiles.
Prescriptions by Age Group
IMS collects for ﬁ  lled prescriptions deidentiﬁ  ed data 
regarding age of patient from the pharmacy systems. We 
thus divided the total number of prescriptions given into 3 
age groups (0–17 years, 18–64 years, >65 years) by using 
age-speciﬁ   c data from IMS that covered prescriptions 
written for oseltamivir from October 9, 2009, through 
March 26, 2010. The percentages were as follows: 0–17 
years, 38.6%; 18–64 years, 53.4%; >65 years, 5.3% (Table 
2). Note that ≈3% of prescriptions ﬁ  lled during this period 
did not have the age of the patient recorded. Therefore, we 
did not include those prescriptions in our analysis.
Prescriptions over Time
We plotted the total number of prescriptions ﬁ  lled per 
week, from the IMS database, against the weekly number 
of estimated pandemic cases for April 24, 2009, through 
March 26, 2010. Estimates of cases for April through 
the end of July 2009 are not available on a weekly basis. 
Thus, all cases were combined into a single estimate for 
that period (1). We combined for the same period all ﬁ  lled 
prescriptions and directly compared cases and prescriptions. 
A notable divergence in the correlation between plots 
of cases and prescriptions over time would indicate the 
possibility of prescriptions being ﬁ  lled for reasons other 
than the immediate treatment of inﬂ  uenza-related illness 
(e.g., stockpiling or use for prophylaxis).
Percentage of Prescriptions Written for Prophylaxis
We assumed in the absence of any data that 10% of 
all prescriptions for these antiviral drugs were written for 
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Table 2. Input values used to estimate influenza antiviral drug–related reduction in hospitalizations during pandemic (H1N1) 2009 
outbreak in the United States, April 24, 2009–March 26, 2010 
Input Initial value  Sources
Distribution of prescriptions by patient age group, y*  IMS Health Xponent database (3)
 0–17    38.6% 
 18–64    53.4% 
 > 65 5.3% 
Prescriptions filled for prophylaxis†  10% Assumption: Some prescriptions were written 
to prevent infection and disease without 
presentation of symptoms. 
Prescriptions for patients who failed to adhere to drug 
regimen or used for personal stockpiles 
20% Assumption: Not all patients will adhere with 
the drug regimen as prescribed. Also, some 
prescriptions were for personal stockpiles 
Antiviral drug effectiveness against hospitalization, by age group, y‡  Literature review (see Table 3) 
 0–17    22%–32% 
 18–64    34%–50% 
 > 65 30%–50% 
Median (range) risk for hospitalization, given pandemic (H1N1) 2009–related illness, 
by age group, y§ 
Reed et al. (4)
 0–17    0.0038  (0.00314–0.00428) 
 18–64    0.00496  (0.0041–0.00558) 
 > 65 0.0155 (0.0128–0.0174) 
*Age group–based distribution of prescriptions based on IMS (IMS Health, Norwalk, CT, USA) that covered prescriptions written for oseltamivir (only) from 
October 9, 2009, through March 26, 2010. 
†These inputs were subjected to sensitivity analyses (see Table 4). 
‡Effectiveness estimate assumes that the patient follows the drug regimen, i.e., these estimates do not allow for those who do not take the complete 
course. Failure to follow prescribed drug regimen was assumed to have 0% effect on reducing risk of hospitalization. This assumption was accounted for 
in a separate input. 
§Risk of per-person hospitalization, given symptomatic illness caused by pandemic (H1N1) 2009 virus. RESEARCH
prophylaxis. This assumption was subject to sensitivity 
analyses (described below). We further assumed that such 
prescriptions essentially had no impact on reduction of 
hospitalizations (Table 2).
Adherence to Drug Regimen and Stockpiling
We also assumed that a total of 20% of all prescriptions 
were for either personal stockpiles (i.e., not written for 
a clinically ill patient at time of prescription) or patients 
who did not sufﬁ   ciently follow the recommended drug 
regimen so that the prescription had no impact on risk of 
hospitalization caused by nonadherence (Table 2). A study 
conducted in the United Kingdom during the (H1N1) 
2009 pandemic found that 76%–80% of the patients did 
complete the full course of prescribed antiviral drugs (5). 
Another study among schoolchildren in London, UK, that 
examined adherence among those offered oseltamivir for 
prophylaxis found that 89% actually took >1 dose and 66% 
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Table 3. Literature review of effectiveness of neuraminidase inhibitors in preventing influenza-related hospitalizations* 
Drug Study  type  Population
Reduction in 
hospitalization point 
estimate (95% CI)  Reference 
Zanamivir Randomized, double-blind, 
placebo-controlled trial 
455 patients residing in Australia, New 
Zealand, and South Africa age >12 y with 
influenza-like symptoms of <36 hours’ duration
NA (14)
Oseltamivir Open-label, multicenter 
international study 
1,426 patients (age range 12–70 y) seeking 
treatment <48 h after onset of influenza 
symptoms 
NA (15)
Oseltamivir Retrospective cohort analysis  The oseltamivir and untreated control groups 
each included 36,751 eligible patients 
22%;
HR 0.78 (0.67–0.91)
(8); 
claims data
Oseltamivir Retrospective cohort study  Oseltamivir and untreated propensity matched 
control groups each included 45,751 eligible 
patients
30% any cause; 
OR 0.71 (0.62–0.83)
(9); 
insurance
claims data
Zanamivir Randomized, double-blind 
studies in 38 centers in North 
America and 32 centers in 
Europe during the 1994–95 
influenza season 
417 adults with influenza-like illness of  
<48 hours' duration were randomly assigned 
to 1 of 3 treatments 
NA (16)
Amantadine/
rimantadine 
Two randomized, double-blind, 
placebo-controlled trials 
|80 patients with laboratory-documented 
influenza A virus (H3N2) illness <2 days' 
duration 
NA (13)
Oseltamivir Combined analysis of 10 
prospective, placebo controlled, 
double-blind trials 
3,564 persons (age range 13–97 y) with 
influenza-like illness enrolled in 10 placebo-
controlled, double-blind trials of oseltamivir 
treatment 
59% any cause 
reduction; 50% 
influenza, at risk 
patients
(7)
Zanamivir Retrospective pooled analysis of 
data; all studies were 
randomized, double-blind, and 
placebo-controlled with 21–28 
day follow-up 
2,751 patients were recruited; of these,  
321 (12%) were considered high risk  
and 154 were randomized to receive 
zanamivir 
NA (17)
Zanamivir Randomized, double-blind, 
placebo-controlled trial in primary 
care and hospital clinics 
356 patients age >12 y were recruited within 
2 d of onset of typical influenza symptoms 
NA (12)
Zanamivir Pooled analyses of secondary 
endpoints
NA (18)
Oseltamivir Randomized controlled trial  726 healthy nonimmunized adults with febrile 
influenza-like illness of <36 hours’ duration 
NA (19)
Oseltamivir Retrospective cohort study  9,090 patients with diabetes and influenza  30% any cause;  
RR 0.70 (0.52–0.94)
(10); 
insurance
claims data
Oseltamivir Retrospective cohort study  The oseltamivir and untreated control groups 
each included 36,751 eligible patients, 50% 
with a claim for oseltamivir, 50% without 
38%;
RR 0.62 (0.52–0.74)
(11); 
insurance
claims data
Oseltamivir Double-blind, stratified, 
randomized, placebo-controlled, 
multicenter trial 
Healthy adults (age range 18–65 y) who 
sought treatment <36 h after onset of 
influenza symptoms 
NA (20)
Oseltamivir Randomized, double blind, 
placebo-controlled study 
Children age 1–12 y with fever (>100°F 
[>38°C]) and a history of cough or coryza  
<48 hours’ duration 
NA (21)
*CI, confidence interval; NA, not applicable; HR, hazard ratio; OR, odds ratio; RR, relative risk. Effect of Antiviral Drug Use during Pandemic
of this group completed (or said they would complete) 
a full 10-day prophylaxis course (6). One of the drug 
effectiveness studies that we reviewed (discussed below) 
and used for model input values asked patients to self-
record adherence; it found that ≈90% of enrolled patients 
were fully compliant (7). Our assumption that 20% of 
prescriptions were for either stockpiling or nonadherence 
was subject to sensitivity analyses (described below).
This allowance for nonadherence also acts as a proxy 
for those who may have started the treatment too late. To 
maximize drug effectiveness in alleviating the duration of 
symptoms, it is recommended that antiviral drug treatment 
start <48 hours after onset of clinical symptoms (2).
Risk for Hospitalization Given Clinical 
Case of Pandemic (H1N1) 2009
We used the risk for hospitalization by age group, given 
clinical illness caused by pandemic (H1N1) 2009, from 
Reed et al. (4) (Table 2). We identiﬁ  ed 17 published studies 
that evaluated the effectiveness of neuraminidase inhibitors 
given inﬂ  uenza-induced clinical illness (7,8–21; Table 3). 
Although many studies were random placebo-controlled 
trials, the studies did not use hospitalizations averted as a 
measured endpoint (13,15–17). We identiﬁ  ed only 4 studies 
that speciﬁ  cally evaluated the impact of the antiviral drugs 
on risk for hospitalization, given clinical illness. One study 
provided an estimate of 50% reduction in the probability of 
inﬂ  uenza-speciﬁ  c hospitalizations (no conﬁ  dence interval 
was published) (7). Three retrospective studies, using health 
insurance claims data, reported effectiveness in reducing 
hospitalizations (any cause) that ranged from 22% to 59%, 
with some variation by age (8–10). For each age group, we 
used lower and upper estimates of effectiveness, from a 
lower estimate of 22% reduction for children 0–17 years to 
an upper estimate of 50% for adults (Table 2).
Calculating Ranges and Sensitivity Analyses
For each level of antiviral effectiveness (lower, upper), 
and for each age group, we calculated the median and lower 
and upper estimates of hospitalizations averted. We also 
conducted sensitivity analyses by altering from 0% to 
30% the assumed percentages of prescriptions written for 
prophylaxis, personal stockpiles, and patients who did not 
adhere to the drug regimen.
Results
Pandemic inﬂ  uenza vaccine became available in week 
40 of 2009 (near the peak of cases). We hypothesized that 
before this date is when doctors would have been most 
likely to try to protect patients by prescribing prophylactic 
courses of antiviral drugs. However, the plot of the 
prescription data against estimated cases over time shows 
a close correlation between the occurrence of pandemic 
(H1N1) 2009 clinical cases and ﬁ  lled prescriptions (Table 
1; Figure). This comparison suggests that antiviral drugs 
were mostly prescribed to treat the occurrence of clinical 
cases of pandemic (H1N1) 2009.
The total number of prescriptions ﬁ  lled  before 
adjustments was 8.2 million (Table 1). After removing 
the prescriptions presumed ﬁ   lled for prophylaxis and 
for patients who failed to adhere to the drug regimen 
or had prescriptions ﬁ   lled for personal stockpiles, 5.7 
million prescriptions were ﬁ  lled that may have reduced 
hospitalizations (Table 4). Most (97%) were ﬁ  lled  for 
oseltamivir, and ≈55% of all prescriptions ﬁ  lled were for 
persons 18–64 years of age, and ≈40% were ﬁ  lled  for 
children 0–17 years of age.
We estimated that the median number of 
hospitalizations averted ranged from 8,427 (lower 6,961; 
upper 9,479) to 12,641 (lower 10,442; upper 14,219) 
(Table 5). Approximately 60% of averted hospitalizations 
were among persons 18–64 years old. The estimated 
hospitalizations averted in children and adults >65 years 
of age (Table 5) were similar. Although adults >65 
years of age received only ≈5% of ﬁ  lled prescriptions 
(Table 4), these prescriptions had a relatively substantial 
impact in averting hospitalizations because the risk for 
hospitalization is higher in this age group than the other 
risk groups (Table 2).
Doubling the assumed percentages of ﬁ  lled 
prescriptions for prophylaxis and personal stockpiles/
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Figure. Number of estimated inﬂ  uenza cases and ﬁ  lled prescriptions 
for inﬂ  uenza antiviral drugs during pandemic (H1N1) 2009 in the 
United States, September 2009–March 2010. The estimates of 
cases for April–August 2009 are not available on a weekly basis. 
During April 12–July 23, 2009, there were 3.1 million cases and 
1.3 million prescriptions ﬁ  lled for inﬂ  uenza antiviral drugs. For the 
month of August 2009, there were 1.6 million cases and 354,000 
prescriptions ﬁ  lled for inﬂ  uenza antiviral drugs. Estimates of cases 
from Shrestha et al. (1); number of prescriptions ﬁ  lled from the IMS 
Health Xponent database (3).RESEARCH
nonadherence from 30% to 60% (i.e., a 100% increase) 
produced only a 40% reduction in median hospitalizations 
averted, from ≈12,600 to 7,200 (Table 6). Thus, the major 
factors inﬂ   uencing hospitalizations averted were total 
prescriptions  ﬁ   lled and (assumed) effectiveness of the 
drugs in preventing hospitalizations.
Discussion
The close correlation between estimated pandemic 
inﬂ   uenza cases and ﬁ   lled prescriptions (Figure) can be 
used as evidence that antiviral drugs were mostly used to 
treat those who were clinically ill (i.e., recommendations 
regarding use were essentially followed). Restricting 
the use of antiviral drugs to treating the clinically ill 
meant that preventing clinical cases from deteriorating 
into severe cases requiring hospitalizations was likely to 
have been among the major effects of antiviral drug use. 
By our estimates, this strategy worked; ≈8,000–13,000 
hospitalizations were averted (Table 5). This reduction 
is equivalent to ≈4–5% of the total estimated pandemic 
(H1N1) 2009–related hospitalizations (1).
We found no other studies with which to compare our 
methods and results. We compared the accuracy of the 
IMS database using unpublished data from the Behavioral 
Risk Factor Surveillance System (BRFSS), conducted in 
49 states (excluding Vermont, the District of Columbia, 
and Puerto Rico). From September 1, 2009, through March 
31, 2010, adults (>18 years old) responding to the BRFSS 
telephone survey were asked whether they had inﬂ  uenza-
like illness (ILI) (deﬁ  ned as having had a fever with cough 
or sore throat) in the month preceding the interview. They 
were also asked if they sought medical care for their ILI 
condition and if they were prescribed antiviral drugs to 
treat their illnesses. Extrapolating the results to the national 
level in the period covered by the survey, we found that 
≈54 million adults reported having ILI symptoms. Of 
those who reported having ILI and sought medical care, 
4.1 million adults reported they were prescribed inﬂ  uenza 
antiviral drugs (oseltamivir or zanamivir) during August 
2009–March 2010. The IMS database recorded 6.86 
million prescriptions in the same period (Table 1); ≈40% 
for those 0–17 years of age (Table 2), leaving ≈4.1 million 
ﬁ  lled prescriptions for adults. This estimate is close to the 
number recorded by the BRFSS survey and further supports 
the idea that few prescriptions were for prophylaxis or 
personal stockpiles.
There are many limitations to this study; the biggest is 
the uncertainty regarding the effectiveness of the drugs in 
preventing hospitalizations. The effectiveness of the drugs 
in reducing risk for hospitalization caused by pandemic 
(H1N1) 2009 may vary considerably from estimates 
reported for nonpandemic strains of inﬂ  uenza virus. The 
data are also limited in that we cannot verify if those 
persons who ﬁ  lled a prescription were actually clinically 
ill from pandemic (H1N1) 2009 or to what extent they 
adhered to the drug regimen. We addressed this issue by 
allowing a wide range in drug effectiveness and a relatively 
large percentage of prescriptions ﬁ  lled for conditions other 
than direct treatment of pandemic (H1N1) 2009.
We were unable, because the available literature did 
not contain sufﬁ  ciently reliable estimates of effectiveness 
of antiviral drugs against death, to estimate the number of 
deaths averted by treatment with antiviral drugs. Shrestha 
et al. (1) estimated that deaths caused by pandemic (H1N1) 
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Table 4. Estimated number of influenza antiviral drugs prescribed for treatment, after adjusting for prescriptions for prophylaxis, 
nonadherence, and personal stockpiling, pandemic (H1N1) 2009 outbreak, United States 
Influenza antiviral drug* 
No. prescriptions, by patient age group† 
Total  0–17 y  18–64 y  >65 y 
Oseltamivir 2,152,915 2,979,711  297,700  5,430,326 
Zanamivir 57,065 78,980  7,891  143,936 
Subtotal‡ 2,209,980 3,058,690  305,591  5,574,262 
*These antiviral drugs were prescribed in a variety of forms (e.g., capsules, tablets, syrup, and inhaled powder). The estimated numbers came from the 
IMS database (3), which records |73% of all prescriptions filled by >50,000 US-based retail pharmacies. IMS then proportionately extrapolates their data, 
based on populations served by pharmacies, to provide weekly estimates of all prescriptions filled in the U.S. for these drugs. The IMS Health Xponent 
database does not cover in-hospital prescriptions. 
†These subtotals, by age group, are the estimates of prescriptions filled to treat pandemic (H1N1) 2009–related clinical illness, after removing the 
prescriptions filled for prophylaxis and for patients who failed to adhere to drug regimen or prescriptions filled for personal stockpiles (see Table 1). The 
total number of prescriptions filled, before adjustments, was 8,177,542 (Table 1). Note that |3% of prescriptions filled during this period did not have age 
of patient recorded, and we omitted those prescriptions from our calculations. 
‡These subtotals, by age group, were the estimates used to calculate the hospitalizations averted as shown in Table 5. 
Table 5. Estimates of hospitalizations averted, by age group, assuming lower and upper estimates of influenza antiviral drug 
effectiveness, United States, 2009–2010* 
Drug effectiveness 
estimate
No. hospitalizations averted, by patient age group, y, median (range) 
0–17 18–64  >65 Total
Lower  1,848 (1,527–2,081)  5,158 (4,264–5,803)  1,421 (1,171–1,595)  8,427 (6,961–9,479) 
Upper  2,687 (2,221–3,027)  7,586 (6,270–8,534)  2,368 (1,951–2,659)  12,641 (10,442–14,219) 
*Estimates of antiviral drug effectiveness are shown Table 2 (source, Table 1). Lower, median, and upper estimates are generated by using the range of 
age-specific probabilities of hospitalization, given influenza-related clinical illness (Table 2). Effect of Antiviral Drug Use during Pandemic
2009 were equivalent to 1.5% of children’s hospitalizations 
and 6% of hospitalizations for persons of all other ages. 
Assuming that hospitalizations averted generate similar 
percentages of deaths averted, then the use of antiviral 
drugs prevented 27–40 deaths in children 0–17 years of 
age and 395–597 deaths in adults of all ages (using median 
values of hospitalizations averted; Table 4).
If during the next pandemic there is a desire to produce 
better quality estimates (perhaps even produce estimates 
at regular intervals during the event), then additional data 
collection systems must be developed to overcome some of 
these limitations. For example, measuring the number of 
prescriptions ﬁ  lled for prophylaxis or personal stockpiles 
or degree of adherence can only reliably be conducted by 
interviewing patients and physicians. Improving estimates 
of impact of ﬁ  lled prescriptions in reducing adverse health 
outcomes during an event will require a large case–control 
study. Policy makers will have to determine if the value 
of such information warrants the investment in such data 
collection systems.
Our results also highlight how the use of inﬂ  uenza 
antiviral drugs during a pandemic is likely to be 
beneﬁ  cial, notably through a presumed reduction in the 
demand for hospital-based resources. Reduced demand 
will also reduce costs of hospitalizations. Assuming a 
cost per inﬂ  uenza-related hospitalization of US$5,000–
$7,000 per patient admitted (adjusted to 2009 dollars) 
(22–26), averted hospitalizations saved ≈$42 million to 
$88 million (based on median values of hospitalizations 
averted; Table 4). A detailed cost-effectiveness analysis, 
including an in-depth consideration of the costs of 
hospitalizing pandemic (H1N1) 2009 patients, is the 
subject of a separate analysis.
If the next inﬂ  uenza pandemic causes greater numbers 
of severe cases and hospitalizations than in 2009, there may 
be an increased demand for antiviral drugs for treatment 
and prophylaxis. Such increased demand could overwhelm 
the existing commercial distribution chains. Therefore, 
public health ofﬁ  cials should consider these estimates as 
an indication of success of treating patients during the 2009 
pandemic and a warning for the need for renewed planning 
to cope with the next pandemic.
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